Theravance (TBPH) Form 4: director exercised 14,000 options

Theravance Biopharma (TBPH) director reported insider transactions on Form 4.

Rhea-AI Filing Summary

Theravance Biopharma (TBPH) director reported insider transactions on Form 4. On 11/11/2025, the reporting person sold 29,500 Ordinary Shares at $18.5, 15,500 shares at $17, and sold 14,000 shares at $18.5 after exercising options at $10.15. These trades were made under a Rule 10b5-1 trading plan adopted on March 14, 2024.

Following the transactions, the reporting person beneficially owned 46,204 Ordinary Shares directly and held 107,878 derivative securities. The 14,000-share option was fully vested and exercisable per its original vesting terms.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider BROSHY ERAN

Role Director

Sold 59,000 shs ($1.07M)

Approx. gross sale proceeds $1.07M

Approx. exercise cost $142K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	14,000	$10.15	$142K
Sale	Ordinary Shares	29,500	$18.50	$546K
Sale	Ordinary Shares	15,500	$17.00	$264K
Sale	Ordinary Shares	14,000	$18.50	$259K

Holdings After Transaction: Share Option (Right to Buy) — 107,878 contracts (Direct); Ordinary Shares — 46,204 shares (Direct)

Footnotes (3)

1. F1. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
2. F2. The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
3. F3. This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did TBPH disclose on this Form 4?

A director reported selling 29,500 shares at $18.5, 15,500 shares at $17, and 14,000 shares at $18.5 after exercising options at $10.15.

Were the TBPH trades under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2024.

How many TBPH shares does the insider own after the trades?

The reporting person beneficially owned 46,204 Ordinary Shares directly after the reported transactions.

What options did the TBPH director exercise?

They exercised options for 14,000 shares at an exercise price of $10.15 and sold those shares the same day.

Were any shares withheld for taxes in these TBPH transactions?

No. The filing states that no shares were withheld for taxes for the exercised-and-sold shares.

How many derivative securities remain after the TBPH transactions?

The reporting person held 107,878 derivative securities following the transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BROSHY ERAN

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/11/2025		S	V	29,500	D	$18.5(1)	61,704	D
Ordinary Shares	11/11/2025		S	V	15,500	D	$17(1)	46,204	D
Ordinary Shares	11/11/2025		S	V	14,000	D	$18.5(2)	46,204	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$10.15	11/11/2025		M	V	14,000		(3)	04/25/2032	Ordinary Shares	14,000	$10.15	107,878	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

2. The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

3. This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

	/s/ Brett Grimaud, Attorney in fact, Attorney-in-Fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.